| abstract |
Compounds having an sPLA2-inhibiting effect are provided, which are compounds of general formula (I), prodrugs of the same, pharmaceutically acceptable salts of both, or hydrates of them, wherein E is N or C-R4; G is N or C-R25; R1 is a carbocyclic group, a heterocyclic group, or the like; one of R?3 and R4 is (L2¿)-(acid group) and the other is hydrogen, with L2 being a group connecting with the acid group); A is an optionally substituted five- to eight-membered cycloalkane or cycloalkene ring; and R?24 and R25¿ are each hydrogen or the like. |